深部静脉血栓症(DVT)市场:现状分析与预测(2024-2032年)

深部静脉栓塞 (DVT) 市场预计将呈现约 8% 的成长率。这主要是由于外科手术尤其是骨科手术的增加，增加了对DVT预防和治疗的需求。此外，影像和诊断工具的进步以及 DVT 治疗研发投资的增加将进一步支持市场成长。例如，2021年，医疗器材巨头波士顿科学公司宣布以高达12亿美元的价格收购行动心臟健康解决方案和远端监控服务开发商Preventice Solutions, Inc.。

依药物类别，市场分为抗凝血剂、肝素等。抗凝血剂预计将占据深部静脉栓塞 (DVT) 市场的最大占有率，因为它们为 DVT 的急性治疗和长期管理提供了重要的治疗选择。 DOAC 将 DVT 治疗与华法林等传统药物分开，使其更安全、更方便。较新的护理点口服抗凝血剂，如阿?沙班、利伐沙班、达比加群和依度沙班，具有某些特点，使其在起效快、药物动力学更好以及相对较少的饮食限制和监测方面优于华法林。因此，由于患者依从性的提高和治疗结果的改善，市场规模不断扩大。此外，该类别中正在进行的现有研究和创新旨在提高疗效、安全措施和患者依从性，因为此类治疗正在全球市场上扩展，以支持 DVT 市场的成长。

根据治疗，市场分为手术、药物和其他。其中，由于药物治疗的进步，特别是抗凝血剂华法林和直接口服抗凝血剂等药物类型，预计药物将占据深部静脉栓塞（DVT）市场的最大占有率。随着目前研究的目标是开发不仅更安全而且更有效的抗凝血剂，市场也在不断增长。生物相似药和仿製药的可用性也使得这些治疗方案变得负担得起且容易获得。此外，包括大手术在内的高风险患者的预防性用药将增加对该类药物的需求，从而刺激全球市场的成长。

根据最终用户，市场分为医院、专科诊所、学术/CRO 等。其中，医院类别预计在预测期内将引领深部静脉栓塞（DVT）市场占有率。初级保健中心和医院通常是出现 DVT 症状的患者的第一个接触点。在医院引入先进的诊断工具和影像技术有助于早期、准确的诊断，这对于有效管理和改善病患治疗效果至关重要。此外，医院是实施预防措施的核心，特别是对于接受手术或长时间卧床不起的患者，对 DVT 的预防和管理做出了重大贡献。

为了更了解深部静脉栓塞（DVT）治疗的市场介绍，市场为北美（美国、加拿大和其他北美地区）、欧洲（德国、英国、法国、西班牙、义大利和其他欧洲地区），根据亚太地区（中国、日本、印度、亚太地区其他地区）和世界其他地区的全球影响力进行分析。北美深部静脉血栓 (DVT) 市场环境在医疗设施、意识和强大的研发方面非常先进。该地区肥胖、久坐生活方式和人口老化等风险发生率较高，因此患者群体庞大，产生了整体业务。诊断开发包括改进影像技术和识别新的生物标记物，有助于更好的诊断和更有效的治疗。此外，专注于新治疗方法（例如新型口服抗凝血剂和微创手术）的强大策略参与者的市场进入进一步推动了市场向前发展。政府加强对医疗保健的支持以及如何预防和管理 DVT 的患者教育也在决定北美 DVT 市场方面发挥着重要作用。

市场上营运的主要公司包括：Medtronic、Aspen Holdings、Novartis AG、Mylan NV、GLENMARK PHARMACEUTICALS LTD.、Hikma Pharmaceuticals PLC、Bristol-Myers Squibb Company、GL Pharma、COBAPHARMA、Boehringer Ingelheim International GmbH等。

目录

第1章 市场简介

• 市场定义
• 主要目的
• 相关利益者
• 限制事项

第2章 调查手法或前提条件

• 调查流程
• 调查手法
• 受访者简介

第3章 摘要整理

• 产业摘要
• 各市场区隔预测
  • 市场成长的强度
• 地区展望

第4章 市场动态

• 促进因素
• 机会
• 阻碍因素
• 趋势
• PESTEL分析
• 需求面分析
• 供给面分析
  • 合併和收购
  • 投资情势
  • 产业洞察：主要新创公司及其独特策略

第5章 价格分析

• 各地区价格分析
• 价格的影响因素

第6章 全球深部静脉血栓症(DVT)市场收益，2022-2032F年

第7章 各类药物的市场分析

• 抗凝血药
• 肝素
• 其他

第8章 不同治疗的市场分析

• 手术
• 药物
• 其他

第9章 各终端用户的市场分析

• 医院
• 专门诊所
• 学术·CRO
• 其他

第10章 各地区的市场分析

• 北美
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 全球其他地区

第11章 价值链分析

• 限制分析
• 市场参与企业一览

第12章 竞争情形

• 竞争仪表板
• 竞争市场定位分析
• 波特的五力分析

第13章 企业简介

• Medtronic
• Aspen Holdings
• Novartis AG
• Mylan N.V.
• GLENMARK PHARMACEUTICALS LTD.
• Hikma Pharmaceuticals PLC
• Bristol-Myers Squibb Company
• GL Pharma
• COBAPHARMA
• Boehringer Ingelheim International GmbH

第14章 缩写与前提条件

第15章 附录

The global deep vein thrombosis (DVT) market relates to the diagnosis, therapy, and prevention of blood clots located in deep veins predominantly in lower limbs, which if left unattended may cause a life-threatening disease known as pulmonary embolism. The market is therefore motivated by these factors including increasing incidences of DVT especially among the aging populace, rising awareness of the condition, improvement in diagnostic tools and treatment options, and increasing risk factors which include obesity, less active lifestyles, and other conditions that are known to cause the condition. Also, the increasing number of healthcare facilities across emerging nations and the incorporation of the latest anticoagulant drugs sustain market growth. Currently, healthcare organizations are striving to address DVT to lessen the risk of adversative events within the global market, enhancement, especially in research and development to benefit patients.

The market for deep vein thrombosis market is set to exhibit a growth rate of about 8%. This is mainly due to the rise in surgical procedures, especially orthopedic surgeries, which increases the need for DVT prophylaxis and treatment. Also, advancements in imaging and diagnostic tools and growing investment in R&D for the treatment of DVT will further boost the market growth. For instance, in 2021, Boston Scientific, a leading medical device company, announced it would acquire Preventice Solutions, Inc., a mobile cardiac health solutions developer, and remote monitoring services, for up to USD 1.2 billion.

Based on the drug class, the market is segmented into anticoagulants, heparin, and others. The anticoagulants category is expected to have the largest market share of the deep vein thrombosis market by offering essential therapeutic options for both acute treatment and long-term management of DVT. DOACs have removed DVT treatment from traditional therapeutics such as warfarin and made it safer and more convenient. New point-of-care oral anticoagulants, including apixaban, rivaroxaban, dabigatran, and edoxaban have certain characteristics and are distinguished from warfarin by a quick onset of action, more favorable pharmacokinetics, limited restrictions in terms of diet and relatively low requirements in terms of monitoring. It has as a result enhanced patient compliance and improved results and therefore the market size has spread. Further, the existing research and innovation conducted in this category are aimed at increasing the effectiveness, safety measures, and patient compliance to fuel the growth of the DVT market as such therapies spread all over the global market.

Based on the treatment, the market is segmented into surgery, drugs, and others. Among these, the drugs category is expected to have the largest market share of the deep vein thrombosis market due to the progression in pharmaceutical care, especially among some types of drugs, such as anticoagulants warfarin and direct oral anticoagulants. The market is also growing constantly because current research has been directed at creating not only safer but also more effective anticoagulants. Also, biosimilar, and generic availability contribute to the affordability and accessibility of these treatment programs. Also, preventive medication for high-risk patients, including the major surgery ones, boosts demand for this medication type, and, thus, will stimulate global market growth.

Based on the end-user, the market is segmented into hospitals, specialty clinics, academic & CROs, and others. Among these, the hospital category is expected to lead the market share of the deep vein thrombosis market during the forecast period. Primary care centers and hospitals are often the first point of contact for patients presenting with DVT symptoms. The adoption of advanced diagnostic tools and imaging technologies in hospitals facilitates early and accurate diagnosis, which is crucial for effective management and improved patient outcomes. Moreover, hospitals are central to implementing prophylactic measures, especially for patients undergoing surgeries or those with prolonged immobility, significantly contributing to the prevention and management of DVT.

For a better understanding of the market adoption of deep vein thrombosis treatment, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The market environment of North America Deep Vein Thrombosis (DVT) is highly advanced in terms of healthcare facilities, awareness, and strong R&D. The incidence of risks like obesity, sedentary lifestyle, and aging population across the region presents a large patient pool for generating overall business. The diagnostic development includes the improvement of imaging techniques and the identification of new biomarkers which contribute to better diagnosis and powerful treatment. Additionally, the market entry of strong strategic players focusing on new therapeutic approaches, including novel oral anticoagulants and less invasive procedures, advances the market further. Increased government support for the coverage of healthcare and the education of patients on how to prevent and manage DVT are other prominent roles that help in the determination of the North American market for DVT.

Some of the major players operating in the market include Medtronic, Aspen Holdings, Novartis AG, Mylan N.V., GLENMARK PHARMACEUTICALS LTD., Hikma Pharmaceuticals PLC, Bristol-Myers Squibb Company, GL Pharma, COBAPHARMA, Boehringer Ingelheim International GmbH.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Global Deep Vein Thrombosis Market
• 2.2. Research Methodology of the Global Deep Vein Thrombosis Market
• 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

• 3.1. Industry Synopsis
• 3.2. Segmental Outlook
  • 3.2.1. Market Growth Intensity
• 3.3. Regional Outlook

4.MARKET DYNAMICS

• 4.1. Drivers
• 4.2. Opportunity
• 4.3. Restraints
• 4.4. Trends
• 4.5. PESTEL Analysis
• 4.6. Demand Side Analysis
• 4.7. Supply Side Analysis
  • 4.7.1. Merger & Acquisition
  • 4.7.2. Investment Scenario
  • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

• 5.1. Regional Pricing Analysis
• 5.2. Price Influencing Factors

6.GLOBAL DEEP VEIN THROMBOSIS MARKET REVENUE (USD MN), 2022-2032F

7.MARKET INSIGHTS BY DRUGS CLASS

• 7.1. Anticoagulants
• 7.2. Heparin
• 7.3. Others

8.MARKET INSIGHTS BY TREATMENT

• 8.1. Surgery
• 8.2. Drugs
• 8.3. Others

9.MARKET INSIGHTS BY END-USER

• 9.1. Hospitals
• 9.2. Specialty Clinics
• 9.3. Academic & CROs
• 9.4. Others

10.MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11.VALUE CHAIN ANALYSIS

• 11.1. Marginal Analysis
• 11.2. List of Market Participants

12.COMPETITIVE LANDSCAPE

• 12.1. Competition Dashboard
• 12.2. Competitor Market Positioning Analysis
• 12.3. Porter Five Forces Analysis

13.COMPANY PROFILED

• 13.1. Medtronic
  • 13.1.1. Company Overview
  • 13.1.2. Key Financials
  • 13.1.3. SWOT Analysis
  • 13.1.4. Product Portfolio
  • 13.1.5. Recent Developments
• 13.2. Aspen Holdings
• 13.3. Novartis AG
• 13.4. Mylan N.V.
• 13.5. GLENMARK PHARMACEUTICALS LTD.
• 13.6. Hikma Pharmaceuticals PLC
• 13.7. Bristol-Myers Squibb Company
• 13.8. GL Pharma
• 13.9. COBAPHARMA
• 13.10. Boehringer Ingelheim International GmbH

14.ACRONYMS & ASSUMPTION

15.ANNEXURE